Mel Gibson on the Joe Rogan Experience #2254, fact-checked

What the evidence shows: Rogan claimed California/Los Angeles spent "$24 billion last year on the homeless" while spending nothing on wildfire prevention. The $24 billion figure traces to a California State Auditor report (April 2024) citing the Legislative Analyst's Office finding that the state "allocated nearly $24 billion for homelessness and housing during the last five fiscal years," a cumulative multi-year total, not a single year's spending. On wildfire prevention, state records show non-zero, substantial funding: CalFire's budget for resource management and fire prevention grew from about $140 million in 2016-17 to roughly $440 million in 2024-25, and peaked above $1.1 billion in 2023-24 due to one-time augmentations, with additional funding flowing through other state departments and conservancies. The claim is misleading on both counts: it compresses a five-year homelessness spending total into "last year," and it mischaracterizes wildfire prevention spending as nonexistent when state budget data show ongoing, substantial funding for that purpose.

What the evidence shows: In March 2019, Governor Gavin Newsom issued a statewide emergency proclamation on forest management, waiving certain environmental reviews to fast-track 35 priority fuel-reduction and forest-thinning projects intended to protect roughly 200 at-risk communities. State officials announced in January 2020 that 34 of 35 projects had been completed. However, a 2021 investigation by CapRadio (aired on NPR) found the Newsom administration overstated the scale of that work: officials claimed about 90,000 acres had been treated, while the state's own underlying data showed the real figure was closer to 11,000-12,000 acres, and statewide fire-prevention work overall had dropped by roughly half heading into California's worst wildfire season on record. PolitiFact and other outlets have also documented that state wildfire-prevention funding fluctuated significantly after 2019, rising during budget-surplus years and facing cuts during deficit years, even as Cal Fire's overall wildfire budget grew substantially over the decade. The claim that Newsom "didn't do anything" overstates the reality: concrete forest-management action was taken and largely completed, but independent reporting shows the administration significantly exaggerated the scale of results relative to what it publicly claimed.

What the evidence shows: Gibson claims La Danta, a Preclassic Maya pyramid at El Mirador in Guatemala, is "literally the biggest pyramid in the world" and larger than any pyramid in Egypt. La Danta is genuinely enormous by volume, estimated at roughly 2.8 million cubic meters, which does exceed the Great Pyramid of Giza's estimated 2.6 million cubic meters, and it is the largest pyramid built by the Maya civilization. However, the claim that it is unqualifiedly the largest pyramid in the world is not well supported: the Great Pyramid of Cholula in Puebla, Mexico, is generally cited by researchers and reference works (including Guinness World Records) as the largest pyramid in the world by volume, at roughly 4.45 million cubic meters, and by base area, nearly twice the footprint of Giza's Great Pyramid. Peer-reviewed lidar survey research has also identified other Mesoamerican monumental constructions, such as Aguada Fénix in Tabasco, Mexico, with a material volume comparable to or exceeding La Danta's, further complicating any single "biggest pyramid in the world" title. La Danta is best described as among the largest pyramids in the world and the largest built by the Maya specifically, not the single largest pyramid on Earth or larger than every structure in Egypt.

What the evidence shows: In 2009, archaeologist J. Craig Argyle, working under Richard Hansen's excavation of the Central Acropolis at El Mirador, Guatemala, uncovered carved stucco panels depicting the Hero Twins (Hunahpu and Xbalanque), the central figures of the Popol Vuh creation narrative. The surrounding ruins are dated to the Late Preclassic period, roughly 300 BC to AD 150, meaning the frieze is on the order of 1,900 to 2,300 years old, not 2,600 years old as Gibson states. The find was nonetheless historically significant: it showed the Popol Vuh's iconography was established many centuries, not necessarily millennia, before the written Quiche-language manuscript was recorded from oral tradition around the 1550s, undercutting the idea that the story was a colonial-era invention influenced by Spanish priests. No mainstream source describes a prior scholarly estimate placing the myth's origin "in the 1300s"; Hansen's own quoted remarks describe the surprise as the story predating the Spanish arrival by "thousands of years," not a revision from a 1300s estimate. The core discovery Gibson references is real and well documented, but his specific age figure of 2,600 years is inflated relative to the published dating of the find, and the "1300s" prior-estimate detail does not match any documented scholarly timeline.

What the evidence shows: LIDAR surveys have genuinely revealed extensive pre-Columbian settlements, causeways, canals, and monumental earthworks in parts of the Amazon basin previously assumed to be pristine wilderness. The best-documented case, published in Nature in 2022, mapped the Casarabe culture in the Llanos de Mojos region of the Bolivian Amazon, finding a four-tiered urban settlement system, including two large sites of 147 and 315 hectares, across an area of roughly 4,500 square kilometers occupied between approximately AD 500 and 1400. That documented footprint, while significant, is a small fraction of the roughly 6 to 7 million square kilometer Amazon basin, so the claim that LIDAR shows most of the Amazon jungle is man-made agricultural land built by cities of millions of people overstates what the research establishes; scientists describe low-density urbanism concentrated in specific regions, not basin-wide replacement of jungle by cities. Researchers have also noted that media coverage of these findings tends toward a "lost cities finally found" narrative that overstates the novelty and scale beyond what the underlying data support. Status: exaggerated.

What the evidence shows: During the 1958 conclave that elected Pope John XXIII, contemporaneous reporting confirms that smoke from the Sistine Chapel chimney appeared white before turning black on at least one occasion on October 26, 1958, the conclave's first day of balloting, causing crowds and Vatican Radio to briefly believe a pope had been elected before the mistake was corrected. The New York Times reported this directly under the headline "Crowds and Vatican Radio Misled Twice by Smoke... Signal White at First... Puff Shows Intended Black," describing confusion consistent in scale with Gibson's account of roughly half an hour. However, this ambiguous smoke occurred during an inconclusive early ballot, not the final ballot that actually elected Cardinal Angelo Roncalli (John XXIII) two days later on October 28, whose white smoke was unambiguous. Gibson's claim that this had "never in history" happened before cannot be confirmed or refuted from available sources, and the incident is widely cited specifically because it was a notable anomaly of this particular conclave rather than a documented singular first. The core event Gibson describes, white smoke followed by black smoke with a period of public confusion, is corroborated by contemporaneous news coverage, but his framing implies it happened at the decisive vote and was a unique first in papal history, both of which are misleading simplifications of the actual, more complicated sequence of events.

What the evidence shows: During the October 2019 Vatican Synod of Bishops for the Amazon, wooden carvings depicting a naked, pregnant indigenous woman were used in a Vatican Gardens tree-planting ceremony attended by Pope Francis and were later displayed in a nearby Rome church. Critics among conservative Catholics labeled the figures a pagan fertility idol called Pachamama, while Vatican officials described them as representing life and fertility rather than an object of worship. The statues were stolen from the church on October 21, 2019 and thrown into the Tiber River, prompting Pope Francis to publicly apologize on October 25 for the theft, stating the statues had been displayed "without idolatrous intentions." No Catholic Mass or liturgy involved formal veneration of the figures as a deity; the episode centers on a contested interpretation of an inculturation display versus an idolatry accusation, not a documented act of Church-sanctioned worship. Characterizing the event as the Pope bringing an idol into the church "to worship" overstates what is documented to have occurred, since the Vatican never described the statues as objects of worship and the Pope's own remarks explicitly denied idolatrous intent.

What the evidence shows: Gibson's claim that the Shroud of Turin's weave dates to the 1st century is contradicted by the best-documented scientific test of the cloth: a 1988 radiocarbon dating study by three independent laboratories (Oxford, Arizona, Zurich), published in Nature in February 1989, which concluded the linen is mediaeval, dating to approximately 1260 to 1390 AD rather than the 1st century. The 'coin over the eyes' theory Gibson attributes to an archaeologist traces to a claim popularized starting around 1979-1981 by Father Francis Filas, who argued image-enhancement analysis showed a Roman coin (associated with the era of Tiberius/Pontius Pilate) over the shroud figure's right eye. This coin theory has never been corroborated in independent peer-reviewed image analysis and is regarded within Shroud scholarship as a disputed, minority interpretation rather than an established finding; critics attribute the perceived markings to pareidolia in the cloth's weave texture rather than an actual imprinted image. The weave-dating claim is contradicted by direct scientific testing; the coin-over-eyes claim remains unsupported by independent, replicated evidence.

What the evidence shows: Rogan read from a 2022 paper published in the journal Heritage (De Caro et al.) that applied a non-standard X-ray scattering method (WAXS) to a single shroud fiber sample and reported an age range consistent with roughly 2,000 years, framing this as compatible with a first-century origin. This omits the most widely accepted scientific dating of the shroud: a 1988 radiocarbon dating study, published in Nature in 1989, in which three independent laboratories (Oxford, Arizona, and Zurich) concurred that the linen dated to approximately AD 1260-1390, placing its origin in the medieval period rather than antiquity. The 2022 WAXS study has not been replicated by independent laboratories, used a single fiber sample rather than the multi-lab cross-checked approach of the 1988 study, and its methodology and small sample size have drawn skepticism from other researchers in the field. The scientific consensus, anchored by the peer-reviewed and multiply-replicated 1988 radiocarbon findings, continues to favor a medieval origin for the shroud; the 2022 study represents a contested minority finding rather than a settled revision of that consensus.

What the evidence shows: Zinjanthropus boisei (OH 5, now classified as Paranthropus boisei) was discovered by Mary Leakey at Olduvai Gorge, Tanzania, in 1959 and formally described by Louis Leakey in Nature that same year as a single, intact robust hominin cranium with massive molars, premolars, and a sagittal crest, not a composite of a human skull and an ape jaw. The fossil has been accepted as genuine by paleoanthropologists for over six decades and remains a type specimen central to the fossil record of early hominins, per the Smithsonian's Human Origins Program. The description Gibson gives, a human skull fused with an ape jaw exposed via testing after being promoted by evolution advocates, instead matches the well-documented Piltdown Man hoax (1912-1953), a set of skull fragments and an orangutan jaw fraudulently combined and later debunked using fluorine dating and other techniques; Piltdown Man is unrelated to Zinjanthropus. Current evidence indicates the claim as stated about Zinjanthropus is false, and it appears to conflate two distinct fossil discoveries.

What the evidence shows: Radiocarbon (carbon-14) dating measures the decay of a radioactive carbon isotope with a known half-life of approximately 5,730 years and is one of the most extensively validated dating methods in archaeology and geoscience. Since the 1960s, radiocarbon measurements have been calibrated against independent, annually-resolved records, including tree rings, ice cores, and cave formations, producing the internationally maintained IntCal calibration curve, most recently updated (IntCal20) using data from nearly 14,000 years of tree rings plus additional archives extending back 55,000 years. At Gobekli Tepe specifically, the site's Pre-Pottery Neolithic age of roughly 11,000 to 9,000 years before present has been established through radiocarbon dating of charcoal and organic sediment samples, cross-checked across multiple laboratories and sample types. While radiocarbon dates carry statistical error margins and require calibration adjustments for factors like past atmospheric carbon-14 fluctuations, these are well-characterized and routinely accounted for rather than being grounds for rejecting the method outright. Scientific consensus, reflected in peer-reviewed methodology reviews, holds that radiocarbon dating is reliable within its known margins of error; there is no credible scientific basis for wholesale rejection of the technique.

What the evidence shows: Gibson directs listeners to Peter Duesberg, a University of California, Berkeley molecular biologist who since the late 1980s has argued that HIV does not cause AIDS. The scientific and medical consensus that HIV causes AIDS was established by the late 1980s and has been reaffirmed by decades of subsequent virological, epidemiological, and clinical research; Duesberg's hypothesis has been reviewed and rejected by mainstream researchers, and a non-peer-reviewed paper in which he continued to dispute HIV causation was later retracted. Duesberg-influenced AIDS denialism had real-world consequences: it shaped South African government health policy under President Thabo Mbeki from 1999, delaying rollout of antiretroviral treatment; a peer-reviewed 2008 epidemiological study estimated that more than 330,000 lives, or roughly 2.2 million person-years, were lost in South Africa because a feasible antiretroviral treatment program was not implemented during that period. Current status: false, thoroughly refuted, with documented public-health harm attributed to the denialist position Gibson recommends investigating.

What the evidence shows: AZT (azidothymidine, zidovudine) was synthesized in 1964 by Jerome Horwitz and screened as a candidate anticancer drug; it was set aside because it failed to show meaningful antitumor efficacy against the cancers it was tested on, not because trials showed it killed cancer patients faster than their disease. Two decades later, in the mid-1980s, researchers repurposed the same compound after discovering it potently inhibited HIV reverse transcriptase, and a 1987 placebo-controlled trial (Fischl et al., NEJM) led to its approval as the first antiretroviral drug for HIV/AIDS. Peer-reviewed pharmacology literature describes AZT plainly as "a failed anticancer drug from the 1960s" that was later found effective against HIV, with no claim in the scientific record that it was withdrawn from cancer use for causing faster death than cancer. AZT does carry real, well-documented toxicities (bone marrow suppression, anemia) at the high doses used in early HIV trials, which may be the origin of loose public claims like this one, but that toxicity issue arose in its HIV use, not as the stated reason for cancer-drug discontinuation. The claim misrepresents the documented history of the drug.

What the evidence shows: At Senate hearings in 2021, Fauci testified that NIH had never funded gain-of-function research at the Wuhan Institute of Virology, testimony Senator Rand Paul disputed and cited in a criminal referral to the Justice Department. Fact-checkers found the dispute centers on a scientific definitional disagreement: NIH-funded EcoHealth Alliance research on bat coronaviruses was judged by NIH staff not to meet the government's technical definition of gain-of-function research, while critics such as Rutgers biosafety researcher Richard Ebright argue it did. No perjury charge has ever been filed against Fauci, and the Department of Justice has not brought any prosecution based on Paul's referral. In January 2025, outgoing President Biden issued Fauci a preemptive pardon covering federal offenses he "may have committed" during his government service, which Fauci accepted while maintaining he committed no crime. As of mid-2026, Fauci's Senate testimony remains a matter of ongoing political dispute rather than an adjudicated instance of perjury.

What the evidence shows: President Biden's December 1, 2024 pardon of his son Hunter Biden was unusually broad: the official text covers not just Hunter's Delaware gun conviction and California tax case, but any federal offenses he "has committed or may have committed or taken part in" from January 1, 2014 through December 1, 2024, per the White House statement as reported by the Associated Press. Rogan's claim that the pardon's start date lines up with Hunter's Burisma involvement is directionally accurate, but the actual start date is 2014, not 2011; Hunter Biden joined the board of the Ukrainian energy company Burisma Holdings in April 2014, matching the pardon's start date rather than the year Rogan cited. On the separate figure invoked in this segment, Department of Justice clemency statistics show Biden granted roughly 1,666 pardons and 13,201 commutations of sentence (about 14,900 combined actions) over his term, a total driven heavily by a December 2024 mass commutation of roughly 1,500 people on home confinement; the commonly cited round number of "over 8,000" clemency actions has circulated in reporting on Biden's record but understates the DOJ's own tallied total of pardons plus commutations, so the specific figure needs care even though Biden's clemency use was historically large by any measure. Overall status: mixed, the pardon's broad retroactive date range is confirmed and roughly matches the Burisma timeline (2014, not 2011), while the exact scale of Biden's total pardons is more complicated than a single round number conveys.

What the evidence shows: Hydroxychloroquine is a well-established drug for treating and preventing malaria and for treating lupus and rheumatoid arthritis, so the claim about its historical use against malaria is accurate. However, for COVID-19, large randomized controlled trials found no benefit: a randomized trial published in the New England Journal of Medicine found hydroxychloroquine did not prevent COVID-19 illness or infection when used as post-exposure prophylaxis, and the U.S. FDA revoked its emergency use authorization for COVID-19 in June 2020, warning that the drug carried a risk of serious heart rhythm problems without demonstrated benefit outside a hospital or clinical trial setting. The framing that price increases or reduced availability reflect suppression of a proven COVID-19 cure is not supported by the clinical evidence; the scientific consensus is that hydroxychloroquine is not an effective COVID-19 treatment, which is why regulators withdrew authorization rather than expanding access. Separately, price or supply changes during 2020 reflected surging demand and shortages tied to its established uses (lupus, rheumatoid arthritis, malaria), not evidence of a suppressed cure.

What the evidence shows: The 2015 Nobel Prize in Physiology or Medicine was awarded to William C. Campbell and Satoshi Omura for discovering avermectin (the basis for ivermectin), specifically recognizing its effect on parasitic worm diseases such as river blindness and lymphatic filariasis; the prize citation does not reference viral infections or COVID-19, which did not exist until five years later. Ivermectin's established, evidence-based use is as an antiparasitic agent, and its effectiveness against SARS-CoV-2 is a separate question tested directly in randomized controlled trials after 2020. A Cochrane systematic review of six randomized trials (2,860 participants) found ivermectin probably makes little or no difference to mortality in COVID-19 outpatients compared with placebo or usual care, with uncertain or no meaningful benefit on hospitalization, ventilation need, or symptom resolution; a separate peer-reviewed meta-analysis reached similar conclusions. Citing the Nobel Prize as evidence that ivermectin works against COVID-19 conflates the drug's proven antiparasitic mechanism with an unrelated and unproven antiviral use. The claim is misleading: the historical fact (a Nobel Prize for antiparasitic research) is accurate, but it is not evidence of the drug's effectiveness against COVID-19.

What the evidence shows: Remdesivir's FDA prescribing information lists acute kidney injury and reduced eGFR/creatinine clearance among reported adverse reactions and laboratory abnormalities in clinical trials, occurring in a small minority of patients (acute kidney injury was cited as a reason for treatment discontinuation in 3 of roughly 200 subjects in one trial arm), not as a common or defining effect of the drug. A 2025 systematic review and meta-analysis in BMC Infectious Diseases, covering one randomized controlled trial and 14 cohort studies, found that among COVID-19 patients with severe renal impairment, remdesivir use was associated with a significantly lower incidence of kidney injury compared with not receiving the drug (risk ratio 0.51, 95% CI 0.27 to 0.97), and no significant increase in mortality. Kidney injury incidence was higher in patients who already had severe renal impairment regardless of remdesivir exposure, not specifically attributable to the drug. The FDA label notes that remdesivir's pharmacokinetics have not been fully evaluated in patients with renal impairment and recommends renal monitoring during treatment, reflecting a precaution rather than an established causal link to kidney failure. Current evidence therefore does not support the claim that remdesivir causes kidney failure; it can be associated with kidney-related lab abnormalities and acute kidney injury in a minority of patients, but cohort and meta-analytic data do not show it as a leading or frequent cause of renal failure, and in high-risk renal patients it has not been shown to worsen kidney outcomes compared with non-use.

What the evidence shows: Gibson's broad claim that every disease afflicting mankind has a natural cure is not a scientifically testable or supported proposition; medicine has no cure for many conditions (e.g., most metastatic solid-tumor cancers, ALS, type 1 diabetes) regardless of source. His more specific anecdote, that ivermectin, fenbendazole, and methylene blue cured three friends' stage 4 cancer, is unverifiable and runs counter to current evidence. Fenbendazole and ivermectin have shown antiproliferative effects only in laboratory cell cultures and animal models, at drug concentrations that would be unsafe or unattainable in humans; no peer-reviewed human clinical trials have demonstrated they cure or treat cancer. A published case report documents a lung cancer patient who developed drug-induced liver injury after self-administering fenbendazole based on social-media claims. Oncologists quoted by the American Cancer Society state there is no proven benefit to fenbendazole for cancer and several potential risks, and that ivermectin has not gone through the rigorous clinical trials needed to establish it as safe or effective for treating cancer in people.

What the evidence shows: A 2020 prospective trial by researchers at Shamir Medical Center and Tel Aviv University in Israel (Hachmo, Hadanny, Efrati et al., published in the journal Aging) gave 35 healthy adults aged 64 and older 60 hyperbaric oxygen therapy sessions over roughly 90 days. The study found telomere length in several immune cell types (T helper, T cytotoxic, natural killer, and B cells) increased by more than 20 percent, with B cells showing the largest gain, and senescent T-helper cells decreased significantly following treatment. Gibson's reference to an Israeli study using a roughly 90-day protocol accurately describes this trial's design and its core telomere finding. However, the study was small, with only 35 participants and no control group receiving a sham treatment, and it measured cellular biomarkers rather than broad clinical health outcomes, so Gibson's characterization of hyperbaric oxygen therapy as "phenomenal for just overall recovery of everything" extends well beyond what this narrow, preliminary research actually demonstrated.